Скачать или смотреть Pathologist's Guide for HER2 Testing in Gastroesophageal adenocarcinoma (GEA)

Accurate HER2 testing has become a cornerstone in the management of gastroesophageal adenocarcinoma, shaping therapeutic decisions and directly impacting patient outcomes. This educational video provides a clear, structured, and evidence-based overview of HER2 testing, tailored specifically for medical students, pathology residents, oncology trainees, and practicing clinicians involved in gastrointestinal cancer care.

🔬 In this video, we cover:

The clinical significance of HER2 in gastroesophageal adenocarcinoma

Testing methodologies – Immunohistochemistry (IHC) and in situ hybridization (ISH)

Scoring systems and interpretation criteria based on current CAP guidelines

How HER2 status informs targeted therapy decisions, including trastuzumab eligibility

💡 Why this matters:
HER2 positivity serves as a predictive biomarker for targeted therapy in gastric and gastroesophageal junction cancers. A solid understanding of the testing algorithm, interpretation nuances, and clinical implications ensures accurate diagnoses and optimal treatment pathways for patients.

🎓 Who should watch:

Pathology and oncology residents preparing for board exams

Medical students seeking to strengthen their foundation in molecular diagnostics

Clinicians and pathologists involved in GI tumor boards

Laboratory personnel performing HER2 testing in GI malignancies

📚 Keywords: HER2 testing, gastroesophageal adenocarcinoma, gastric cancer, molecular pathology, CAP/ASCO guidelines, trastuzumab, IHC, ISH, targeted therapy, GI oncology education.

✨ Join Our Medical Learning Community

If you found this video helpful, like, share, and subscribe for more high-yield medical education content. Share your questions or clinical experiences with HER2 testing in the comments below — your insights help the entire community learn together.